Hydroxychloroquine treatment for COVID-19 & QTc prolongation | Vascular Solutions recalls catheters

Treating COVID-19 patients with hydroxychloroquine, alone or in combination with azithromycin, is associated with an increased risk of QTc prolongation, according to two new studies published in JAMA Cardiology.

A group of cardiovascular societies, including the American College of Cardiology (ACC) and American Heart Association (AHA), has published a new guidance designed to help providers resume important procedures and diagnostic tests during the COVID-19 pandemic.

Vascular Solutions is recalling all Langston Dual Lumen Catheters distributed from July 12, 2019, to March 10, 2020.

There’s a reason to feel quite optimistic about these numbers—the rise comes from an updated definition of hypertension, one first suggested by the American College of Cardiology and American Heart Association.

The high mortality rates from COVID-19 among black patients and other racial/ethnic minorities put a much-needed spotlight on the “deep-rooted failures” of the U.S. healthcare system to improve care for cardiovascular disease (CVD), according to a new commentary.

E-cigarettes can cause just as much damage to a person’s arteries and blood vessels as traditional cigarettes, according to a new study published in the Journal of the American Heart Association.

As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.